Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

Study Overview
=================
Brief Summary
-----------------
All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.

Detailed Description
-----------------
Sample selection - Select communities of 20,000 to 40,000 populations in Zhongshan City and Wuzhou city as the investigators' fields. Participants recruitment Subjects voluntarily attend this screening study Informed consent - Informed consent forms will be collected at the recruitment. Questionnaires. Face-to-face interviews are conducted by well-trained investigators. Tests and follow up At initial screening, all participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, P85-Ab et al. And in males, EBV-DNA will be tested. Based on EBNA1-IgA, VCA-IgA, participants will be stratified into high, moderate and low risk. Screening positive include P85-Ab positive, high or moderate risk of NPC or EBV DNA positive. The rest will be screening negative. During the initial screening and following up, people with high risk or P85-Ab positive will refer to the diagnostic workup for NPC. Briefly, fiberoptic endoscopy and pathological biopsy will be performed by otorhinolaryngologists. Screening positive people not diagnosed as nasopharyngeal carcinoma in the first year will be followed up annually. EBV DNA single positive people will refer to the diagnostic workup for NPC in the third year of follow up. The rest of the blood samples will be stored at the biobank of Zhongshan People's Hospital for further research. All subjects will also be followed by record linkage to Cancer Register and Population Register.

Official Title
-----------------
Searching for Early Detection Biomarkers of Nasopharyngeal Carcinoma in Zhongshan City

Conditions
-----------------
Nasopharyngeal Carcinoma

Intervention / Treatment
-----------------
* Biological: Blood and saliva
* Diagnostic Test: P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA
* Diagnostic Test: Fiberoptic endoscopy and biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject residents in Zhongshan City or Wuzhou City Subject has no medical record of nasopharyngeal carcinoma ECOG 0-2 Subject is able to comprehend, sign, and date the written informed consent document to participate in the study. Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study. Exclusion Criteria: Subject has heavy cardiovascular, liver or kidney disease. Subject has contraindications to nasopharyngeal fiberoptic endoscopy.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Screening cohort<br>30-69 years old healthy participants in Zhongshan and Wuzhou. | Biological: Blood and saliva<br>* Collect blood and saliva samples from participants<br>Diagnostic Test: P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA<br>* Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.<br>Diagnostic Test: Fiberoptic endoscopy and biopsy<br>* Screening participants will refer to fiberoptic endoscopy and biospy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of different EBV associated biomarkers | To compare the sensitivity and specificity of different EBV associated biomarkers for NPC | 5 years | 
| Positive and negative predictive values of different EBV associated biomarkers | To compare the positive and negative predictive values of different EBV associated biomarkers for NPC | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number needed to screen to identify one nasopharyngeal carcinoma | To compare the number of participants needed to screen identify one nasopharyngeal carcinoma for different biomarkers | 5 years | 
| Early diagnosis rate of nasopharyngeal carcinoma | To compare the early diagnosis rate of different biomarkers for nasopharyngeal carcinoma | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Screening, Nasopharyngeal Carcinoma, Biomarker